Description
Key facts
Cell type:Jurkat,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%,
Disease:Non-Hodgkin Lymphoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CD1A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD1a also known as T6 antigen or CD1 is a protein with an estimated molecular mass of 37 kDa. It is expressed mainly on the surface of Langerhans cells in the skin and dendritic cells in the thymus. CD1a belongs to the CD1 family which presents lipid antigens to T cells. The protein is an important marker in immunophenotyping of these dendritic cells making it useful in flow cytometry applications.
Biological function summary
CD1a participates in the immune system by presenting lipid and glycolipid antigens to T lymphocytes including natural killer T (NKT) cells. It forms a complex with β2-microglobulin which is essential for its proper function and antigen presentation. CD1a expression helps differentiate between types of dendritic cells with CD1a-positive cells often engaging in specific responses to microbial lipid antigens.
Pathways
CD1a plays a significant role in the antigen presentation pathway particularly in lipid antigen presentation to T cells. This is important for initiating immune responses. It interacts with related proteins such as CD1b and CD1c which also present lipid antigens. CD1a has implications in innate and adaptive immunity and can influence pathways involved in microbial recognition and elimination.
CD1a is associated with certain skin conditions like Langerhans Cell Histiocytosis and psoriasis. It is involved in the pathogenesis of these diseases by affecting immune responses in the skin. In Langerhans Cell Histiocytosis CD1a-positive cells accumulate abnormally. Additionally CD1a is often studied alongside related proteins like CD207 (Langerin) to understand these conditions better.
